Trump pressures 17 pharma CEOs to cut US drug prices

WASHINGTON, July 31 (Reuters) – President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday.
Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas.

Related Posts

IndiaAI, ICMR sign MoU to advance AI in healthcare

New Delhi- IndiaAI on Thursday signed a memorandum of understanding (MoU) with the Indian Council of Medical Research (ICMR) to advance healthcare outcomes through the responsible and scalable application of…

Illegal drug manufacturing racket busted in Baddi area

In a major crackdown on the illegal drug trade, the Drugs Control Administration (DCA), Himachal Pradesh, on Friday busted a racket involved in the illicit manufacturing and storage of narcotic…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

IndiaAI, ICMR sign MoU to advance AI in healthcare

IndiaAI, ICMR sign MoU to advance AI in healthcare

Illegal drug manufacturing racket busted in Baddi area

Illegal drug manufacturing racket busted in Baddi area

US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

Nishant as Health Minister, Bihar is all set to witness a New Dawn of Healthcare

Nishant as Health Minister, Bihar is all set to witness a New Dawn of Healthcare

Six Women Develop Serious Complications After C-Section

Six Women Develop Serious Complications After C-Section

Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected

Cracks Down on Pharma Biological Firm in Bagru; Labeling Violations, Unapproved Claims and Quality Lapses Detected